Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

References

• Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430 - 6; http://dx.doi.org/10.1038/nm0496-430; PMID: 8597953
   PubMed Web of Science ®Google Scholar
• Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132 - 5; http://dx.doi.org/10.1016/j.vaccine.2005.01.057; PMID: 15755583
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007; 25:2990 - 3; http://dx.doi.org/10.1016/j.vaccine.2007.01.014; PMID: 17280753
   PubMed Web of Science ®Google Scholar
• Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335 - 43; PMID: 9102222
   PubMed Web of Science ®Google Scholar
• Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038 - 40; http://dx.doi.org/10.1016/j.vaccine.2007.01.032; PMID: 17289225
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267 - 70; http://dx.doi.org/10.1016/j.vaccine.2009.01.064; PMID: 19200841
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7:Suppl 60 - 7; http://dx.doi.org/10.4161/hv.7.0.14563; PMID: 21546794
   PubMed Web of Science ®Google Scholar
• Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7:Suppl 108 - 14; http://dx.doi.org/10.4161/hv.7.0.14571; PMID: 21263229
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Hum Vaccin 2010; 6:297 - 308; http://dx.doi.org/10.4161/hv.6.4.10172; PMID: 20372079
   PubMed Web of Science ®Google Scholar
• Peña SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 1997; 158:2680 - 8; PMID: 9058801
   PubMed Web of Science ®Google Scholar
• Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121 - 5; http://dx.doi.org/10.1126/science.282.5386.121; PMID: 9756476
   PubMed Web of Science ®Google Scholar
• Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol 2007; 178:77 - 84; PMID: 17182542
   PubMed Web of Science ®Google Scholar
• Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404 - 12; PMID: 11342666
   PubMed Web of Science ®Google Scholar
• Rook GAW, Lowrie DB, Hernàndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols?. J Infect Dis 2007; 196:191 - 8; http://dx.doi.org/10.1086/518937; PMID: 17570105
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:2110 - 9; http://dx.doi.org/10.1016/S0140-6736(10)60393-5; PMID: 20488515
   PubMed Web of Science ®Google Scholar
• Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; http://dx.doi.org/10.1371/journal.pone.0013837; PMID: 21079801
   PubMedGoogle Scholar
• Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006; 25:5994 - 6002; http://dx.doi.org/10.1038/sj.onc.1209585; PMID: 16652150
   PubMed Web of Science ®Google Scholar
• Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971 - 8; PMID: 9869111
   PubMed Web of Science ®Google Scholar
• Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1:30 - 3; PMID: 11249680
   PubMed Web of Science ®Google Scholar
• Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164 - 75; http://dx.doi.org/10.1016/S0140-6736(08)61036-3; PMID: 18620952
   PubMed Web of Science ®Google Scholar
• Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742 - 51; http://dx.doi.org/10.1016/j.vaccine.2007.01.112; PMID: 17321015
   PubMed Web of Science ®Google Scholar
• Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133 - 41; http://dx.doi.org/10.1089/hum.1997.8.17-2133; PMID: 9414261
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219 - 26; http://dx.doi.org/10.1006/mthe.2002.0647; PMID: 12161188
   PubMed Web of Science ®Google Scholar
• Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599 - 602; http://dx.doi.org/10.2174/1389450033490740; PMID: 14577648
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307 - 32; http://dx.doi.org/10.1016/S0065-2660(05)53012-8; PMID: 16240999
   PubMed Web of Science ®Google Scholar
• Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044 - 52; http://dx.doi.org/10.1002/jgm.753; PMID: 15756713
   PubMed Web of Science ®Google Scholar
• Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352; PMID: 16648574
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191 - 204; http://dx.doi.org/10.1016/j.vaccine.2005.08.103; PMID: 16216394
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; http://dx.doi.org/10.1155/2011/549281; PMID: 21437226
   PubMed Web of Science ®Google Scholar
• Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717 - 21; http://dx.doi.org/10.1073/pnas.78.12.7717; PMID: 6801660
   PubMed Web of Science ®Google Scholar
• Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583 - 90; http://dx.doi.org/10.1084/jem.157.2.583; PMID: 6600487
   PubMed Web of Science ®Google Scholar
• Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543 - 9; PMID: 3261754
   PubMed Web of Science ®Google Scholar